A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of Nebulized IN-006 in Healthy Volunteers
Latest Information Update: 13 Oct 2021
At a glance
- Drugs Regdanvimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors Inhalon Biopharma
- 07 Oct 2021 According to an Inhalon Biopharma media release, the study is being funded in part by a contract awarded by the U.S. Army Medical Research & Development Command (USAMRDC).
- 07 Oct 2021 According to an Inhalon Biopharma media release, the first patient has been dosed in the study.
- 07 Oct 2021 Status changed from not yet recruiting to recruiting, according to an Inhalon Biopharma media release.